Abstract

Evidence-based recommendations on abatacept (Orencia), adalimumab (Humira), etanercept (Enbrel) and tocilizumab (RoActemra) for treating juvenile idiopathic arthritis in children, young people and adults.

The recommendations also apply to biosimilar products of the technologies that have a marketing authorisation allowing the use of the biosimilar for the same indication.

Is this guidance up to date?

We reviewed the evidence in December 2018. We found nothing new that affects the recommendations in this guidance.

Next review: This guidance will be reviewed if there is new evidence that is likely to affect the recommendations.

Guidance development process

How we develop NICE technology appraisal guidance

This guidance replaces NICE technology appraisal guidance on the use of etanercept for the treatment of juvenile idiopathic arthritis (TA35).